Treatment of chronic hepatitis c with interferon with or without ursodeoxycholic acid: A randomized prospective trial

Journal of Clinical Gastroenterology

Volumn 26, Issue 2, 1998, Pages 130-134

  Abdelmalek, Manal F ^a   Harrison, M Edwyn ^a   Gross Jr , John B ^a   Poterucha, John J ^a   Gossard, Andrea A ^a   Spivey, James R ^a   Rakela, Jorge ^a   Lindor, Keith D ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Chronic hepatitis C; Interferon; Treatment; Ursodeoxycholic acid

Indexed keywords

PLACEBO; RECOMBINANT ALPHA2B INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG SCREENING; FEMALE; HEPATITIS C; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BIOPSY; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, VIRAL; TRANSAMINASES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0031953492     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199803000-00009     Document Type: Article

References (30)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized double blind placebo controlled trial. N Engl J Med 1989; 231:1506-10.
3. Benhamou JP, Hopf U, Rizzetto M, et al. Non-A non-B (C) study group. Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to 12 months post-treatment [abstract]. Hepatology 1995;22:151A.
4. Lindsay KL, Davis GL, Schiff E, et al. Long-term response to higher doses of interferon (IFN) alfa-2b treatment of patients with chronic hepatitis C: a randomized mullicenter trial. Hepatology 1996;24:1034-40.
5. Poynard T, Bedossa P, Chevallier M, et al. Multicenter study group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
6. Podda M, Battezzati PM, Zuin M, et al. Long-term treatment with different regimens of recombinant interferon alfa in chronic hepatitis C [abstract]. Hepatology 1995;22:120A.
7. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.
8. Chemello L, Bonetti P, Cavalletto L, et al., TriVeneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-6.
9. Bellobuono A, Mondazzi L, Tempini S, et al., Italian Multicentre Study Group on Treatment of Chronic Hepatitis C. Comparison between fixed and escalating doses of alpha interferon treatment in chronic hepatitis C [abstract]. Hepatology 1995;22:152A.
10. Fong TL, Valinluch B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994;107:196-9.
11. Smith JP. Treatment of chronic hepatitis C with amantadine hydrochloride [abstract]. Gastroenterology 1996;110:1330A.
12. Schvarcz R, Ando Y, Sonnerborg A, et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23(suppl 2):17-23.
13. Chemello L, Cavalletto L, Bernadinello E, et al. The effects of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23(suppl 2):8-12.
14. Caldwell SH, Dickson RC, Driscoll C, et al. A pilot study using piroxicam with interferon a2b in the retreatment of refractory hepatitis C [abstract]. Gastroenterology 1995;108:1043A.
15. Bellobuono A, Vicari F, Ideo G, et al. Antioxidant drugs combined to alpha interferon in chronic hepatitis C unresponsive to alpha interferon: a randomized controlled multicenter study [abstract]. Gastroenterology 1997;112:1225A.
16. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570-80.
17. Crosignani A, Battezzati PM, Setchell KDR, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991;13:339-44.
18. Rolandi E, Fransechini R, Cataldi A, et al. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur J Clin Pharmacol 1991;40:473-6.
19. Kiso S, Kawata S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyl-transpeptidase level. J Gastroenterol 1996;31:75-80.
20. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long term follow-up. Am J Gastroenterol 1995;90:263-9.
21. Bonnand AM, Poupon R, Queeneau PE, et al. Interferon alfa and ursodeoxycholic acid combination versus interferon alone in the treatment of chronic hepatitis C: results of a randomized trial [abstract]. Hepalology 1996;24:A1107.
22. Delich P, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C (HCV) with ursodeoxycholic acid (UDCA) in patients who failed interferon (IFN) therapy [abstract]. Gastroenterology 1995;108:A1057.
23. Pigozzi R, Sorbara R, Reffiani A, et al. Adjuvant tauro-ursodeoxycholic acid (T-UDCA) therapy for interferon (IFN) treatment of chronic hepatitis C [abstract]. Hepatology 1996;24:A1108.
24. Garson JA, Tedder RS, Briggs M, et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet 1990;355:1419-22.
25. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
26. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
27. Möhler M, Seipp U, Töx B, et al. Effect of ursodesoxycholic acid on liver enzymes and titer of anti-HCV-IGM and semiquantitative HCV RNA in patients with subtyped chronic hepatitis C [abstract]. Gastroenterology 1995;108:A1125.
28. Takano S, Ito Y, Yokosuk O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-64.
29. Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. J Gastroenterol Hepatol 1996;11:1155-60.
30. Boucher E, Jouanolle J, Andre P, et al. Interferon and ursodeoxycholic acid combination therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-7.